1. Home
  2. LRE vs CTXR Comparison

LRE vs CTXR Comparison

Compare LRE & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LRE
  • CTXR
  • Stock Information
  • Founded
  • LRE 2001
  • CTXR 2007
  • Country
  • LRE Japan
  • CTXR United States
  • Employees
  • LRE N/A
  • CTXR N/A
  • Industry
  • LRE
  • CTXR Biotechnology: Pharmaceutical Preparations
  • Sector
  • LRE
  • CTXR Health Care
  • Exchange
  • LRE Nasdaq
  • CTXR Nasdaq
  • Market Cap
  • LRE 17.6M
  • CTXR 14.6M
  • IPO Year
  • LRE 2023
  • CTXR N/A
  • Fundamental
  • Price
  • LRE $1.30
  • CTXR $0.84
  • Analyst Decision
  • LRE
  • CTXR Strong Buy
  • Analyst Count
  • LRE 0
  • CTXR 2
  • Target Price
  • LRE N/A
  • CTXR $54.50
  • AVG Volume (30 Days)
  • LRE 3.8K
  • CTXR 679.0K
  • Earning Date
  • LRE 01-01-0001
  • CTXR 05-13-2025
  • Dividend Yield
  • LRE N/A
  • CTXR N/A
  • EPS Growth
  • LRE N/A
  • CTXR N/A
  • EPS
  • LRE 0.29
  • CTXR N/A
  • Revenue
  • LRE $117,804,154.00
  • CTXR N/A
  • Revenue This Year
  • LRE N/A
  • CTXR N/A
  • Revenue Next Year
  • LRE N/A
  • CTXR N/A
  • P/E Ratio
  • LRE $4.09
  • CTXR N/A
  • Revenue Growth
  • LRE 8.82
  • CTXR N/A
  • 52 Week Low
  • LRE $1.10
  • CTXR $0.81
  • 52 Week High
  • LRE $13.76
  • CTXR $26.25
  • Technical
  • Relative Strength Index (RSI)
  • LRE 53.35
  • CTXR 28.63
  • Support Level
  • LRE $1.15
  • CTXR $0.81
  • Resistance Level
  • LRE $1.49
  • CTXR $1.02
  • Average True Range (ATR)
  • LRE 0.12
  • CTXR 0.09
  • MACD
  • LRE 0.00
  • CTXR 0.01
  • Stochastic Oscillator
  • LRE 50.00
  • CTXR 10.09

About LRE Lead Real Estate Co. Ltd

Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

Share on Social Networks: